Invesco NASDAQ Biotechnology ETF
IBBQ
11 hedge funds and large institutions have $10.7M invested in Invesco NASDAQ Biotechnology ETF in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
22% more funds holding
Funds holding: 9 → 11 (+2)
14.86% less ownership
Funds ownership: 55.28% → 40.42% (-15%)
33% less capital invested
Capital invested by funds: $15.9M → $10.7M (-$5.19M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.92M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$597K |
| 3 |
CIAS
Capital Investment Advisory Services
Raleigh,
North Carolina
|
+$195K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.8K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$6.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$3.02M |
| 2 |
Citigroup
New York
|
-$2.37M |
| 3 |
Morgan Stanley
New York
|
-$1.01M |
| 4 |
AF
Apexium Financial
Dallas,
Texas
|
-$18.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Mirae Asset Global Investments
Seoul,
South Korea
| $6.56M | – | – | – |
|
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1.94M | +$1.92M | +92,687 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $970K | +$597K | +28,787 | +164% |
|
|
CGL
4
Clarius Group LLC
Seattle,
Washington
| $445K | – | – | – |
|
|
AF
5
Apexium Financial
Dallas,
Texas
| $410K | -$18.2K | -879 | -5% |
|
|
CIAS
6
Capital Investment Advisory Services
Raleigh,
North Carolina
| $197K | +$195K | +9,400 | New |
|
|
7
Bank of America
Charlotte,
North Carolina
| $86K | -$3.02M | -145,895 | -97% |
|
|
8
UBS Group
Zurich,
Switzerland
| $26K | +$18.8K | +905 | +259% |
|
|
9
Morgan Stanley
New York
| $22K | -$1.01M | -48,937 | -98% |
|
|
AIP
10
Ahrens Investment Partners
Lafayette,
Louisiana
| $8K | – | – | – |
|
|
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $6.28K | +$6.22K | +300 | New |
|
|
12
Citigroup
New York
| – | -$2.37M | -100,000 | Closed |
|
IBBQ Hedge Fund Activity: Q1 2022 in Review
11 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Invesco NASDAQ Biotechnology ETF (IBBQ) for Q1 2022, worth a combined $10.7M — down 33% from $15.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IBBQ positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $1.92M. The largest seller was Bank of America, cutting an estimated $3.02M.
- 11 institutional investors held Invesco NASDAQ Biotechnology ETF (IBBQ) as of Q1 2022, up from 9 in Q4 2021.
- Funds reported $10.7M of Invesco NASDAQ Biotechnology ETF stock for Q1 2022, down 33% quarter-over-quarter.
- 3 funds opened new Invesco NASDAQ Biotechnology ETF positions in Q1 2022 and 1 closed out, a net change of +2 holders.
- The largest Invesco NASDAQ Biotechnology ETF buyer in Q1 2022 was Royal Bank of Canada, an estimated $1.92M added.
- The largest Invesco NASDAQ Biotechnology ETF seller in Q1 2022 was Bank of America, an estimated $3.02M sold.
Based on aggregated 13F filings for Q1 2022.